Steve Kolb explains NN101-SMA
View Steve Kolb's video announcement of the NN101 SMA study.
View Steve Kolb's video announcement of the NN101 SMA study.
Article Summary: In February, 2012, the US National Institute for Neurological Disorders and Stroke (NINDS) is due to announce the first study to be supported by the National Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). With this ambitious new network, NINDS aims to facilitate the progress of new drugs from the laboratory to the clinic, specifically at the stage of phase 2 trials and biomarker validation studies. New therapies for neurological diseases are undoubtedly needed, but how can NeuroNEXT make a difference?
Please visit the NIH page for information related to the NeuroNEXT Clinical Trials (U01 Clinical Trial Optional) funding mechanism. The FOA is available for applications beginning January 5, 2018, through January 8, 2021.